KK
Kristen Kluska Cantor Fitzgerald Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
40
Avg Return
Past Year
Past Year
16%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
84%
Neutral
16%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Upgraded
| $16 |
86%
upside
| 1 | +11% |
0
%
| 9 Mar ‘26 3 months ago |
|
|
|
Neutral
Upgraded
| $9 |
68%
downside
| 2 | -67% |
0
%
| 2 Mar ‘26 3 months ago |
|
|
|
Overweight
Maintained
| $125 |
78%
upside
| 3 | +9.7% |
0
%
| 17 Feb ‘26 3 months ago |
|
|
|
Overweight
Maintained
| $19 |
205%
upside
| 2 | +27% |
0
%
| 15 Jan ‘26 5 months ago |
|
|
|
Neutral
Downgraded
| $14.50 |
0%
upside
| 1 | +18% |
–
| 19 Dec ‘25 5 months ago |
|
|
|
Overweight
Maintained
| $48 |
165%
upside
| 2 | +4.9% |
0
%
| 17 Dec ‘25 6 months ago |
|
|
|
Overweight
Maintained
| $24 |
584%
upside
| 2 | +22% |
0
%
| 8 Dec ‘25 6 months ago |
|
|
|
Overweight
Initiated
| $19 |
309%
upside
| 2 | -12% |
0
%
| 1 Dec ‘25 6 months ago |
|
|
|
Overweight
Maintained
| $24 |
91%
upside
| 3 | +11% |
0
%
| 6 Nov ‘25 7 months ago |
|
|
|
Neutral
Maintained
| $38 |
14%
upside
| 3 | – |
–
| 5 Nov ‘25 7 months ago |
|
|
|
Overweight
Maintained
| $63 |
44%
upside
| 2 | +16% |
0
%
| 30 Sep ‘25 8 months ago |
|
|
|
Overweight
Reiterated
| $105 |
314%
upside
| 2 | -11% |
0
%
| 5 Sep ‘25 9 months ago |
|
|
|
Overweight
Reiterated
| $118 |
54%
upside
| 3 | +23% |
0
%
| 3 Sep ‘25 9 months ago |
|
|
|
Overweight
Reiterated
| $74 |
20%
upside
| 2 | +39% |
0
%
| 27 Aug ‘25 9 months ago |
|